|Articles|September 1, 2001

Interferon alfa-2b appears to lesson chances of recurrence

Intermediate dosing of agent may enhance distant metastatis-free intervalfor high-risk patients

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME